Adam Feuerstein @adamfeuerstein · May 8
$GILD should swoop in and buy $VRTX while stock is down before the positive vote on Tuesday....If not VRTX then look for ACHN ?
No Currency No Bond ONLY GOLD....
When the ECB cut the Deposit rate for a second time September 2014 to negative 0.20 from positive 0.10, the EUR/USD price was located at about 1.3179 and at that juncture, it already broke the 5 and 10 year averages in the 1.3200 and 1.3300's. December 2014, the EUR/USD would travel further to break below the 14 and 16 year averages at 1.2550 and 1.2235. But January 2015 was the big month for the Euro as its descent would see every average break from 16 to 62 years. Viewed in this context, one would understand why the EUR/USD lacked any meaningful correction.
ACHN Buy out for GILD is eminent How much Billions that Time will decide ..Longer the Time more Billions would be added. ...Your Candle stick size would depend on that..
Plans for the future
By Annie Gilroy
May 11, 2015 4:05 AM
Barrick Gold (ABX) touched upon its near-term project pipeline during its 1Q15 earnings call. It has completed a pre-feasibility study at Turquoise Ridge and expects to complete three more pre-feasibility studies on Nevada-based projects in 2015. Most of these are for higher-grade underground mines, which should help the company generate stronger margins along with volume growth.
New discovery at Alturas
The company says that it has discovered a potentially attractive gold deposit at Alturas in Chile. It’s located in one of company’s core areas, the Andean region of Chile. The reserve is primarily oxide, similar to Barrick’s Veladero mine. It could, however, have significantly higher grades. The company says that given its significant potential, it’s moving quickly on the discovery and expects to report an initial resource estimate with its 2015 full-year results.
Lumwana mine restart drives copper guidance upgrade
Barrick Gold previously reported that due to an increase from 6% to 20% in the tax regime of Zambia, its Lumwana copper mine might have to be put on care and maintenance. The mining economics there had become uneconomical. But it turns out that the Zambian government has proposed amendments that will replace the 20% rate with a rate of 9%. At this revised rate, Barrick Gold says it can generate positive free cash flow at current copper prices.
As a result of this development, management has increased its 2015 guidance for copper production to between 480 million and 520 million pounds, up from between 310 million and 340 million pounds.
Prospecting in Northern Chile
Barrick is also partnering with QPX (Quantum Pacific Exploration), a company that uses innovative strategies to increase the probability of copper discovery. With the help of QPX, Barrick wants to explore for copper deposits in the highly prospective areas of northern Chile. Barrick could see added production as a result of any copp
Wrong answer! 9 months for delivery after getting pregnant. Read Overview of Phase 2 Proxy Study for 8 weeks and 6 weeks Carefully! Thats why I don't like school bunking kids!
Overview of Phase 2 Proxy Study Design and Top-line Results
This ongoing study is a Phase 2 open-label, randomized, partial-crossover study to evaluate the efficacy, safety, and tolerability of eight- and six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, once daily, in treatment-naïve genotype 1 HCV-infected patients. Initially, eighteen patients were enrolled, including six observational patients, into an eight-week treatment cohort.
Following the achievement of 100 percent SVR12 (12/12) in the eight-week cohort, the six-week treatment cohort was initiated. In all, eighteen patients were enrolled, including twelve active and six observational patients. Mean baseline HCV RNA viral load was 10 million (7 log10) IU/ml, range 2 million (6.23 log10) - 97 million (7.99 log10) IU/ml, including seven patients with baseline HCV RNA viral load exceeding 6 million (6.78 log10) IU/ml. Of the 12 active patients enrolled, seven patients were genotype 1a and five were genotype 1b.
Twelve weeks after the completion of therapy, 100 percent (12/12) achieved SVR12, independent of baseline viral load, gender, and IL28B status, in the six-week treatment arm. Additionally, one hundred percent of patients (12/12) in the eight-week treatment duration arm have achieved SVR24. The combination of ACH-3102 and sofosbuvir was well-tolerated with no serious adverse events, no discontinuations due to adverse events, and no clinically significant laboratory or ECG abnormalities.
"The achievement of 100% SVR12 after six weeks of treatment with a dual NS5A-nucleotide regimen, even in patients with high baseline viral load who would otherwise require extended duration treatments, supports our belief that ACH-3102 can unleash the potential of this combination to drive down treatment duration," commented Dr. David Apelian, Executive Vice President of Clinical Development and Chief Medical Officer at Achillion. "We are currently preparing to initiate our SPARTA Phase 2 program which evaluates short treatment durations with our proprietary once-daily regimens of ACH-3102 and ACH-3422, with or without sovaprevir, for treatment naïve genotype 1 HCV patients. In parallel, we plan on exploring sofosbuvir-sparing regimens that will leverage shorter durations of sofosbuvir in combination with ACH-3102 and sovaprevir as part of our global development program."
Achillion achieves 100% SVR12 in six-week regimen with combination of ACH-3102 and sofosbuvir for treatment-naïve genotype 1 HCV
Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102
- Achillion achieves 100% SVR12 in six-week regimen with combination of ACH-3102 and sofosbuvir for treatment-naïve genotype 1 HCV -
- Achillion to initiate 4-week treatment regimens based on the strength of ACH-3102 antiviral data -
NEW HAVEN, Conn., Feb. 9, 2015 (GLOBE NEWSWIRE) --Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients. The primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after completion of therapy. One hundred percent of patients (12/12) in the six-week treatment duration arm achieved SVR12, which included patients with high baseline viral load.
"The ability to further shorten treatment duration to only six weeks and maintain excellent SVR12 rates remains the goal for clinicians and patients, and I am pleased that these Phase 2 results support that goal. The profile of ACH-3102, represents an important and exciting treatment option to shorten treatment duration for patients infected with HCV," commented Professor Edward Gane, M.D., Deputy Director and Hepatologist, New Zealand Liver Transplant Unit, Auckland City Hospital in New Zealand, and Lead Investigator in the Phase 2 study of ACH-3102 and sofosbuvir and the ACH-3422 nucleotide inhibitor program.
Dr. Milind Deshpande, President and Chief Executive Officer of Achillion, commented, "Our goal is to deliver short duration, widely accessible treatments to all HCV patients. We believe that these results with ACH-3102 represent the shortest duration and highest response achieved to date with any two-drug, direct-acting antiviral regimen for HCV. Given the exceptional profile of ACH-3102, we will now be evaluating four- and six-week treatment durations that leverage all of our HCV assets including ACH-3102, ACH-3422, and sovaprevir."
Critical Alerts For Yelp, SunEdison, Adobe Systems, Achillion Pharmaceuticals and El Pollo Loco Released By InvestorsObserver
The greatest challenge is to design one drug that works more quickly for people with varying degrees of the disease, or who are also suffering from separate maladies.
“Hepatitis C has a complicated patient population,” Stefan Zeuzem, a liver disease specialist in Frankfurt who consults for drugmakers developing hepatitis treatments, said in an interview at a liver disease conference in Vienna. “The more advanced the disease, the longer the treatment required.”
While new combination drugs from Gilead and Achillion have shown high cure rates after six weeks of therapy, those results were for patients who are the easiest to treat.
“The failure rate was unexpectedly high” in Gilead’s study among those who had taken other medicines and relapsed, Edward Gane, lead investigator for both the Gilead and Achillion studies, said in an interview. The Gilead trial, presented last week, also showed that patients with cirrhosis, one of the major complications of hepatitis, had a lower cure rate than those with less severe forms of the disease.
China needs to Buy Tons and Tons of Gold !